Our Opinion

Bioblast Pharma Ltd. is on the Cruelty Free Investing use of animals list because they conduct Pre-clinical studies of their drugs on animals to assess a product’s safety profile.

Evidence:

Colin Foster, BioBlast’s President and CEO commented: “Our in vivo proof-of-concept studies demonstrate Cabaletta’s efficacy in reducing Ataxin3 aggregates, reducing neural markers for neural damage and preventing typical phenotypic deterioration in animal models. Read the full article.

Company Description

Bioblast Pharma Ltd (BioBlast) is an Israel-based development-stage biopharmaceutical company. The Company is focused on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic and metabolic diseases. It focuses on therapeutic platforms that offer solutions for several diseases that share a common pathophysiological mechanism, which are the functional changes that accompany a particular syndrome or disease. [Source: GoogleFinance]

Website: https://bioblastpharma.com